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The aim of the study was to determine the maximum tolerated dose (MTD), the dose limiting toxicity (DLT), and the
pharmacokinetic profile (Pk) of bendamustine (BM) on a day 1 and 2 every 3 weeks schedule and to recommend a safe phase II dose
for further testing. Patients with solid tumours beyond standard therapy were eligible. A 30-min intravenous infusion of BM was
administered d1þd2 q 3 weeks. The starting dose was 120mgm
 2 per day and dose increments of 20mgm
 2 were used. Plasma
and urine samples were analysed using validated high-performance liquid chromatography/fluorescence assays. Fifteen patients were
enrolled. They received a median of two cycles (range 1–8). The MTD was reached at the fourth dose level. Thrombocytopaenia
(grade 4) was dose limiting in two of three patients at 180mgm
 2. One patient also experienced febrile neutropaenia.
Lymphocytopaenia (grade 4) was present in every patient. Nonhaematologic toxicity including cardiac toxicity was not dose limiting
with this schedule. Mean plasma Pk values of BM were tmax 35min, t1/2 49.1min, Vd 18.3lm
 2, and clearance 265mlmin
 1m
 2. The
mean total amount of BM and its metabolites recovered in the first micturition was 8.3% (range 2.7–26%). The MTD of BM in
the present dose schedule was 180mgm
 2 on day 1þ2. Thrombocytopaenia was dose limiting. The recommended dose for future
phase II trials with this schedule is 160mgm
 2 per day.
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The cytotoxic agent bendamustine (BM) hydrochloride (Cytosan
s,
Treanda
s, Ribomustin
s, IMET-3393; ZIMET-3393; 5-[bis(2-chlor-
oethyl)amino]-1-methylbenzimidazolyl-2-butyric-acid) is a multi-
functional alkylating agent with a purine-like ring system and a
novel mechanism of action. Ozegowski and Krebs (1963) first
synthesised it in 1963 in former Eastern Germany . Owing to a
hydrochloride residue to the butyric acid side chain, BM is soluble
in water (Gandhi, 2002). Its alkylating activity has been described in
preclinical studies, where – at least in high dosages – it causes the
formation of intrastrand and interstrand crosslinks between DNA
bases (Gandhi, 2002). In comparison with other more commonly
used alkylating agents, such as cyclophosphamide or phenylalanine
mustard, more DNA double-strand breaks are formed when used in
equitoxic dosages (Barmam Balfour and Goa, 2001). In addition,
DNA damage produced by BM is supposed to be repaired via base-
excision repair rather than the alkylguanine transferase mechanism
(Niemeyer et al, 2004). This suggests a different mode of action,
which was recently confirmed when gene expression profiling
analysis identified a different gene profile activated by BM (Leoni
et al, 2004; Niemeyer et al, 2004). It offers an explanation for the
lack of cross-resistance with other alkylating agents, as observed in
anthracycline-resistant breast cancer cell lines and cisplatin-
resistant ovarian cancer cell lines (Strumberg et al, 1996). Treatment
with BM also induces a concentration-dependent apoptosis as
evidenced by changes in Bcl-2 and Bax expression profiles in
chronic B-cell lymphocytic leukaemia (Konstantinov et al, 2002;
Schwa ¨nen et al, 2002). Synergism was demonstrated when BM was
combined with fludarabine (Chow et al, 2001). Further evaluation
indicated that the synergistic effects were associated with the
downregulation of inhibitors of apoptosis proteins, prostate-
apoptosis-response-gene 4, and death-associated protein (Daxx)
and with enforced caspase activation (Chow et al, 2003).
Preclinical studies indicated that BM is selectively taken up from
the plasma in the liver where it undergoes extensive first pass
metabolism involving conjugation with glutathione (Bezek et al,
1996; Teichert et al, 2005). Similar to other mustards containing the
bis-chloroethyl moiety, two products of chemical hydrolysis, namely
monohydroxy-bendamustine (OH-BM) and dihydroxy-bendamus-
tine (Di-OH-BM), have been detected. The elimination of un-
changed BM and these metabolites is primarily renal (Weber et al,
1991; Preiss et al, 1998; Teichert et al, 2003). However, the main
biotransformation products N-dimethyl-BM and g-OH-BM are
excreted with the bile (Bezek et al, 1991; Preiss et al, 1998; Teichert
et al, 2006). In preclinical studies, acute toxicity is observed in bone
marrow and intestines, while the kidneys, testes, prostate, and the
lymphatic tissues are prone to subacute toxicity (Horn et al, 1985).
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sAfter its preclinical development, BM was first tested in multiple
myeloma in 1969 and went into clinical use from 1971 onwards.
After Germany’s reunification, BM was marketed in the whole
country on the basis of a so-called ‘fictitious’ registration. As a
result of a re-registration procedure in Germany, the first full
registration was granted in 2005. Only recently the drug was re-
discovered in the United States and a whole range of preclinical
and clinical trials were initiated. Just now clinical trials are being
started in Japan. Especially, its antilymphoma activity and the lack
of complete cross-resistance with the other alkylators fuels
ongoing scientific interest.
Previous phase II studies of monotherapy BM demonstrated
impressive remission rates combined with good tolerability in
relapsing and/or refractory non-Hodgkin’s lymphoma (NHL)
(Heider and Niederle, 2001; Bremer, 2002; Weidmann et al, 2002;
Friedberg et al, 2004). Moreover, in combination with vincristine
and prednisone (BOP), BM demonstrated higher 5-year survival
rates (61 vs 46%) compared to cyclophosphamide containing
standard regimen (Herold et al, 2006). Furthermore, the doublet
BM/rituximab is evaluated in NHL because of its synergistic
activity and high response rate (70%) in phase II trials (Kanekal
et al, 2004; Rummel et al, 2005a,b). Bendamustine is also actively
investigated in multiple myeloma where the combination with
prednisone proved to be more efficacious than the standard
treatment: melphalan and prednisone (time to treatment failure: 14
vs 10 months, P¼0.02) (Po ¨nisch et al, 2006). In solid tumours,
BM’s lack of cross-resistance with other alkylating agents, its
favourable toxicity profile, and the fact that it shows anticancer
activity in second line and in the salvage setting in patients with
pretreated metastatic breast cancer (MBC) (Ho ¨ffken et al, 1998;
Zulkowski et al, 2002), non-small cell lung cancer (NSCLC) (Reck
et al, 1998), and small cell lung cancer (SCLC) (Schmittel et al,
2007) make it a valuable addition to the armamentarium of active
anticancer drugs. Recently, a randomised phase III study
compared cyclophosphamide, methotrexate, and 5-fluorouracil
(CMF) with a comparable schedule in which cyclophosphamide
was replaced by BM (BMF). The BMF schedule demonstrated
superior progression-free survival in first-line MBC (8.2 vs 6.7
months for CMF; Von Minckwitz et al, 2005).
The earlier studies suggested a variety of schedules in which
single agent BM could be used: that is, as a short intravenous
infusion of 50–60mgm
 2 for 5 consecutive days every 4 weeks;
120mgm
 2 for 2 consecutive days every 3–4 weeks or 60mgm
 2
weekly. The most commonly observed toxicities were both
haematologic (leukocytopaenia, thrombocytopaenia, lymphocyto-
paenia, and anaemia), and nonhaematologic, in particular gastro-
intestinal disturbances (nausea, vomiting, and mucositis)
(Schrijvers and Vermorken, 2002). Some cardiac toxicity was also
described, consisting primarily of intermittent tachycardia (Reck
et al, 1998; Scho ¨ffski et al, 2000a,b).
Only recently formal phase I testing resumed. These included a
day 1þ8 q 4 weeks schedule, a weekly schedule, a day 1 q 3 weeks
schedule – all in solid tumour patients – and a day 1þ2q3 – 4
weeks in B-cell CLL (Bergmann et al 2005; Lissitchkov et al, 2006;
Rasschaert et al, 2007; Scho ¨ffski et al, 2000a,b).
The present report summarises the toxicity and pharmaco-
kinetic profile (Pk) of BM with the latter schedule when used in
patients with solid tumours with the aim to define maximum
tolerated dose (MTD), dose-limiting toxicity (DLT) and to
recommend more precisely a safe dose for future phase II studies
with this schedule.
PATIENTS AND METHODS
Patient selection
Patients with histologically confirmed advanced cancer refractory
to standard therapy or for which no standard therapy existed were
eligible. Patients were adult individuals, legally competent, in a
reasonably good general condition (World Health Organization
(WHO) performance status 0–2), with a life expectancy of 43
months, and were included after obtaining informed consent.
Those with disturbed liver function (aspartate (AST), alanine
aminotransferases (ALT), and bilirubin 42 times the upper limit
of normal values), disturbed renal function (serum creatinine
42 ULN), inadequate bone marrow function (Hb p8.0gdl
 1,
WBC p4.0 10
9l
 1, platelets p100 10
9l
 1), inadequate cardiac
function (left ventricular ejection fraction (LVEF) o50%), those
with evidence of active infection or uncontrolled infection,
epilepsy, or peptic ulcer and those with suspected central nervous
system involvement were excluded from the study.
All patients provided signed informed consent. In accordance
with the Declaration of Helsinki, International Conference on
Harmonization - Good Clinical Practice (ICH-GCP) – guidelines
and applicable local laws. The Ethics Committee of the University
Hospital of Antwerp approved the protocol.
Study design
This was a single-centre, open-label nonrandomised phase I trial to
study the Pk and to define the safety and tolerability of BM
hydrochloride administered by a day 1þ2 every 3 weeks schedule.
Starting dose was 120mgm
 2 per day and dose increments of
20mgm
 2 per day were used, provided that no dose-limiting event
occurred in the first cycle of the previous dose level. The study
treatment was administered on an outpatient basis.
The individual treatment was continued until disease progres-
sion or unacceptable toxicity. Anti-emetic therapy was left to the
discretion of the clinician treating the patient. The concomitant
use of other cytotoxic or experimental agents was not permitted
and haematopoietic growth factors (G-CSF, GM-CSF or erythro-
poietin) were not routinely given.
The study drug was supplied by Ribosepharm GmbH (Munich,
Germany) in sterile vials containing 100mg BM hydrochloride to
be administered in 500ml of 0.9% saline over 30min as a
peripheral or central intravenous infusion.
Definition of DLT, MTD and schedule of dose escalation
Dose-limiting toxicity was defined as (1) any Xgrade 3
nonhaematologic toxicity (except for alopecia and inadequately
treated nausea or vomiting), (2) grade 4 anaemia or thrombo-
cytopaenia, (3) leukopaenia (o1.5 10
9l
 1) or thrombocytopae-
nia (o50 10
9l
 1) for 414 days (lymphocytopaenia was not
considered dose limiting), or (4) febrile neutropaenia.
Initially, three patients were to be included at each dose level. If
no DLT developed, dose escalation would continue. If one of three
patients developed a DLT, another three would be enrolled at that
same dose level. If at least two of three patients or at least two of
six patients developed an identical DLT, that dose level would be
classified as the MTD. If no more than one of six patients
developed DLT, dose escalation would proceed.
No intra-patient dose escalation was permitted. Once three
patients completed the first cycle defined as 21 days after the first
BM administration and had been observed for acute toxicity,
patients were allowed to start treatment at the next dose level.
Assessment of toxicity
Patients were assessable for safety analysis when at least one cycle
was administered and when one observation was carried out
afterwards. Monitoring of safety and tolerability was carried out by
the National Cancer Institute of Canada, Common Toxicity
Criteria (NCIC-CTC version December 1994). The evaluation of
side effects was based on weekly outpatient visits with laboratory
and clinical investigations, medical history, and a full physical
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sexamination. The following investigations were carried out before
each cycle: toxicity assessment; physical examination, including
heart rate, blood pressure, body temperature, and body weight;
blood tests including blood sedimentation rate, coagulation
parameters, differential blood count, serum analysis including
sodium, potassium, calcium, creatinine, blood urea nitrogen
(BUN), uric acid, AST and ALT, alkaline phosphatase, g-glutamyl
transpeptidase, lactate dehydrogenase, bilirubin, creatine kinase
(CK), CK-MB, protein, albumin, c-reactive protein, glucose, and
tumour markers. Urinalysis, urinary sediment, and creatinine
clearance (calculated by Cockroft–Gault equation) were also
evaluated.
Toxicity assessment, physical examination, pulse rate, differ-
ential blood count, and serum parameters (creatinine, BUN, AST,
ALT, CK, CK-MB, and glucose) were repeated weekly.
For the assessment of potential cardiac toxicity, electrocardio-
grams (ECG) were performed on days 1 (before and after treatment
administration), 2, 8, and 15 of each cycle. Left ventricular ejection
fraction (LVEF) (evaluated by MUGA scan) was initially deter-
mined only before the first administration of BM. However, when
we observed cardiac toxicity in another phase I study using a day 1
q 3 weeks schedule, which was running in our department at the
same time (Rasschaert et al, 2007), the study was put ‘on hold’ after
recruitment of six patients (three each in dose levels 120 and
140mgm
 2). Only after the other phase I trial was completed, the
protocol was amended for evaluating the LVEF every other cycle
and recruitment resumed. In addition, we assessed troponin-t,
prothrombotic parameters (platelet function, aggregation tests
(with ristocetine, collagen, epinephrine)) and clotting factors (eg,
Von Willebrand antigen) in a subset of patients. Furthermore, the
wall tracking system was used to assess flow-mediated and
nitroglycerin-mediated vasodilation of the brachial artery as
described previously (Pyke and Tschakovsky, 2005). These para-
meters determine endothelial function and by themselves have been
correlated to exercise tolerance and coronary heart disease.
Assessment of response
Response was assessed every other cycle. For this, WHO criteria
were used: complete response, complete disappearance of tumour
and signs, or symptoms of disease; partial response, 450%
reduction in tumour (calculated as the product of the tumour’s
greatest diameter and its perpendicular measurement) for a
minimum of 4 weeks; minimal response, 25–50% reduction in
tumour for a minimum of 4 weeks; stable disease (SD), o25%
reduction or o25% progression for a minimum of 4 weeks; and
progressive disease (PD), 425% increase in tumour size.
Pharmacokinetics
Plasma samples Five millilitres (ml) venous whole blood was
drawn on day 1, from the arm contralateral to the infusion arm
into 7.5ml monovettes containing lithium heparin at the following
time points: 0 (predose baseline), 10, 20, 30 (end of infusion), 35,
40, 45, 50, 60, 75, 90, 105, 120, 180, 280, 360, and 480min.
Immediately upon collection, the samples were transferred in ice
water and spun in a cold (4–61C) centrifuge at 2000g for 4min.
The separated plasma was immediately deep-frozen at  701Ci n
three aliquots of approximately 0.8ml in prelabelled 1.2ml tubes
(Nalgene, Nalge Nune International, Rochester, NY, USA).
Urine samples Before the first treatment (on the day before or on
the treatment day), a 2ml predose urine sample was collected from
each patient. The urine produced after starting the drug infusion
(first micturition) was completely collected throughout cycles 1
and 2. Two 1ml aliquots of each collection were stored at  701C.
Plasma and urine samples were analysed using a validated high-
performance liquid chromatography/fluorescence assay.
Pharmacokinetic evaluation Pharmacokinetic calculations were
performed by means of the pharmacokinetic software package
WinNonlin Pro 4.0 (Pharsight Corporation, USA, 2002). Para-
meters were determined by non-compartmental analysis (NCA).
The NCA was based on a model requiring a constant infusion of
the drug. The peak plasma concentration (Cmax) and the time to
reach Cmax (tmax) were read directly from the concentration–time
data. The area under the plasma concentration–time curve (AUC)
was calculated by the trapezoidal method from the first to last
measurable concentration and extrapolated to infinity (AUCInf)
using the ratio of the last measured concentration to the terminal
slope. The latter was determined by log-linear regression analysis
of the terminal phase. Clearance and volume of distribution (Vd)
were normalised to body surface area.
Statistical analyses
Interpretation of the clinical data was by SPSS 11.5 statistical
software (SPSS Inc., Chicago IL, USA); only descriptive statistics
are given.
Results are presented in absolute numbers or as group medians
with the range or mean values with standard deviation (s.d.) or
standard error (s.e.) as indicated.
RESULTS
Patient characteristics
A total of 15 patients were enrolled in this phase I trial over an
extended time period (September 2000 to December 2003). Their
characteristics are summarised in Table 1. The median WHO
performance status of these patients was 1 (range 0–2).
All patients had received prior treatment for metastatic or
recurrent disease and were refractory to prior chemotherapy. The
median number of prior chemotherapy regimens was 3 (range 1–5
regimens); in fact, 12 of the 15 patients had received 3 or more
chemotherapeutic regimens. None of the patients had received BM
before.
Bendamustine administration
A total of 35 cycles were administered with a median of 2 cycles
(range 1–8). Five patients received only two cycles; of the patients
who received three or more cycles, one received four cycles, one
six cycles and one eight cycles. All patients received the full
planned dose and no dose reductions were needed.
Of the seven patients who stopped treatment after one cycle,
three patients did not complete the first observation period of 21
days and underwent surgery for PD. Four patients stopped therapy
after one cycle, and did not receive a second because of death
owing to tumour progression (1), refusal (1), PD (1) and one
patient stopped treatment because of dose-limiting haematologic
toxicity.
Only two cycles were delayed. In one case (second cycle at
160mgm
 2) this was due to haematologic toxicity (thrombocyto-
paenia maximally grade 3 but no DLT). In the second case
(sixth cycle at 160mgm
 2), this was carried out on request of the
patient.
Safety
The worst nonhaematologic and haematologic toxicities per
patient experienced during the first cycle are shown in Table 2.
No treatment-related deaths occurred.
Nonhaematologic toxicity Nonhaematologic toxicity was gener-
ally mild and not dose-limiting. The most frequently encountered
side effects were fatigue (13 patients – 87%), nausea (10 patients –
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s67%), loss of appetite (10 patients – 67%), and vomiting (8 patients
– 53%).
One patient developed a grade 2 allergic reaction after the
administration of BM at a dose of 140mgm
 2. He experienced
shortness of breath with mild stridor, flushes, and tachycardia. All
effects were reversible after drug administration was interrupted
(day 1 of the first cycle of BM); the second dose (day 2) could be
completed uneventfully following a slow infusion rate and the use
of corticosteroids prophylactically. No alopecia or peripheral
neuropathy was observed.
None of the eligible patients had clinically relevant coronary
heart disease; however four patients entered the study with
abnormal ECGs: one showed a right bundle branch block, the
second a left anterior fascicular block, the third a first degree atrio-
ventricular block, only one – the fourth showed non-specific T-
wave abnormalities. Serial ECGs were performed according to
protocol and showed cardiac toxicity. Sinus tachycardia (grade 1
NCI-CTC) was present in four patients (one patient at 120, one at
140, and two at 160mgm
 2). Premature supraventricular com-
plexes were seen in one patient at 140mgm
 2 and premature atrial
complexes and ventricular extrasystoles were observed in another
patient at 160mgm
 2. No therapeutic intervention was needed.
Furthermore, one patient (at 140mgm
 2) with a left anterior
fascicular block before study entry developed ECG signs compa-
tible with an infero-septal infarction on day 22 of the first cycle, at
which time he was hospitalised because of gastro-intestinal
bleeding and generalised malaise. Since no clinical symptoms of
acute myocardial infarction or elevated CK/CK-MB were recorded,
the ECG changes were evaluated as disease related (due to
anaemia).
However, since ischaemic cardiac toxicity was observed in our
day 1 every 3 weeks phase I study with the same drug, an analysis
was performed in four patients at dose level 160mgm
 2 to identify
any endothelial risk factors (see assessment of toxicity). No
definitive relation between any of the tested parameters, use of the
study drug and endothelial (dys-) function or cardiac ischaemia
could be demonstrated. Furthermore, only one patient showed a
decrease in LVEF (of 11%) after the second cycle. Unfortunately,
none of the patients at the higher dose level (180mgm
 2) received
more than one cycle; therefore no additional information on
potential cardiotoxic effects at this higher dose could be obtained.
In conclusion, cardiac toxicity in this phase I study was present,
but not considered as being dose limiting. All cases of sinus
tachycardia were of mild/moderate severity and self-limiting.
Haematologic toxicity Three patients presented with tumour-
related anaemia (Hb o10gdl
 1) before treatment. Two of them
Table 2 Incidence of selected adverse events: first cycle, all causalities
120mgm
 2 (n¼3) 140mgm
 2 (n¼3) 160mgm
 2 (n¼6) 180mgm
 2 (n¼3)
Grade (NCIC-CTC) All/grade 3–4 All/grade 3–4 All/grade 3–4 All/grade 3–4
Blood/bone marrow
Haemoglobin 2/0 2/0 5/1 2/1
Platelets 1/0 2/0 3/0 3/2
Leukocytes 0/0 1/0 3/0 2/1
Neutrophils 0/0 0/0 1/0 1/1
Lymphocytes 3/3 3/3 6/6 3/3
Febrile Neutropaenia 0/0 0/0 0/0 1/1
Constitutional symptoms
Fatigue 2/1 3/1 4/0 1/0
Allergy 0/0 0/0 0/0 1/0
Gastrointestinal
Nausea 3/0 2/0 2/0 2/0
Vomiting 2/0 2/0 1/0 1/0
Aiorejia 1 /1 2/0 3/0 2/0
Constipation 0/0 1/0 0/0 1/0
Cholinergic symptoms
Dry mouth 0/0 0/0 1/0 1/0
Cardiovascular symptoms
Deep vein thrombosis 1/1 1/1 0/0 0/0
Tachycardia 1/0 1/0 2/0 0/0
Table 1 Patient characteristics
Number of patients (n¼15)
Gender
Male 8
Female 7
Age
Median (years) 55
Range (years) 29–80
WHO performance status
02
18
25
Pretreatment
Immunotherapy 3
Chemotherapy 15
Surgery 14
Radiation 5
Tumour type
Colorectal carcinoma 4
Soft tissue sarcoma 3
Renal cell cancer 2
Melanoma 2
Oesophageal cancer 1
Adrenocortical carcinoma 1
Osteosarcoma 1
Mesothelioma 1
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sreceived a blood transfusion and one used darbepoetine before the
start of the first cycle (protocol violation). Eight patients developed
anaemia (two at 120mgm
 2, one at 140mgm
 2, three at
160mgm
 2, and two at 180mgm
 2) for which blood transfusions
were given in seven patients.
Myelosuppression, in particular thrombocytopaenia, was dose
limiting (Table 2). Thrombocytopaenia grade 4 occurred in two
patients at 180mgm
 2. It presented late during the first cycle
(nadir on days 22 and 28, respectively) and was long-lasting (18
and 11 days, respectively). Both patients suffered from soft tissue
sarcoma and had been extensively pretreated with alkylating
agents; one had also received radiotherapy. One of these two
patients also experienced febrile neutropaenia.
With two out of three patients at the 180mgm
 2 dose level
having thrombocytopaenia grade 4, this dose level was defined as
the MTD. The dose level of 160mgm
 2 was safely administered to
six patients; the latter dose therefore was defined as the
recommended dose for phase II studies.
Lymphocyte depletion (grade 4) was present in every patient on
day 8 and at any dose level. Although lymphocyte depletion was
long-lasting, no opportunistic infections were observed. However,
six patients needed antibiotics for symptomatic infections (cystitis
(2), streptococcal sepsis (1), acute bronchitis (1), fever of unknown
origin (1), febrile neutropaenia (1)).
Tumour response
No clinical or radiologic responses were observed in these patients.
However, four patients had stable disease for variable periods of
time.
One patient with a soft tissue sarcoma and one with renal cell
cancer, treated at the 160 and 140mgm
 2 dose level, respectively,
experienced stabilisation of disease during six and eight cycles. A
third patient with renal cell cancer, treated at the 120mgm
 2 dose
level, had stable disease after four cycles, but stopped therapy
owing to a streptococcal sepsis. A fourth patient with colorectal
cancer achieved a stable disease after two cycles at 160mgm
 2 but
refused further therapy.
Pharmacokinetic profile
The pharmacokinetic parameters of BM in plasma calculated by
NCA are listed in Table 3. Plasma Pk data were available for only
six patients while urine Pk data were available for five patients.
The mean elimination half-life of BM in plasma was 49.1min,
the volume of distribution 18.3lm
 2 and the clearance
265mlmin
 1m
 2. These figures do not significantly differ from
those observed in our day 1 q 3 weeks study (Rasschaert et al,
2007). Maximum plasma concentrations of BM were found at the
end of the infusion. In the present study, all mean values of tmax
and t1/2 estimated for the metabolites OH-BM, g-OH-BM and
N-dimethyl-BM were in the range of 35–64min, and did not
demonstrate a clear dose dependency.
Owing to low concentrations (below detection level) and
interfering peaks, only limited Pks could be drawn for Di-OH-
BM. Therefore, no complete pharmacokinetic evaluation was
feasible for this metabolite.
Urinary excretion of BM and its metabolites
About 93.5% of the amount excreted in urine was BM and its
hydrolysis products, expressed as the sum of parent compound
and all identified metabolites. The mean total amount of BM and
its metabolites recovered in the first micturition was 8.3%, ranging
from 2.7 to 26.0%, expressed as percentage of the administered
dose.
DISCUSSION
In this phase I study with BM hydrochloride given by a 30min
intravenous infusion for two consecutive days every 3 weeks,
thrombocytopaenia grade 4 was the DLT at 180mgm
 2 per day.
Other important toxicities were long-lasting lymphocytopaenia,
observed from the first cycle onwards and present in every patient
irrespective of the given dose, and some nonhaematologic toxicity,
that is, fatigue, loss of appetite, nausea and vomiting.
The recommended dose for further phase II testing is
160mgm
 2 day. At this and lower doses, tachycardia was
observed; however, this did not seem to be of clinical relevance.
An analysis in a subset of four patients, at dose level 160mgm
 2,
gave no evidence of platelet dysfunction or endothelial dysfunc-
tion, which could be attributed to the use of BM.
Overall toxicity has been quite similar in the different phase I
studies performed with BM in patients with solid tumours.
However, some schedule dependency has been noted.
In a day 1þ8 q 3 weeks schedule, Scho ¨ffski et al (2000a)
determined an MTD at 140mgm
 2, and reported fatigue and dry
mouth as DLTs. They also observed a high incidence of
lymphocytopaenia without opportunistic infections. Later the
same investigators conducted a phase I study of weekly BM
(Scho ¨ffski et al, 2000b) and reported an MTD of 80mgm
 2, with
cholinergic events, fatigue and fever as DLTs. Again a near
absolute lymphocytopaenia was noted (11 out of 12 patients). Flow
cytometric studies demonstrated that BM had a deleterious effect
on all lymphocyte subsets, but most prominently on B cells.
In a third phase I trial in which a single dose of BM every 3
weeks was studied, the MTD was determined at 280mgm
 2. The
DLTs in this schedule were fatigue and cardiac toxicity (Rasschaert
et al, 2007). At the MTD, ST segment and T-wave changes
suggested ischaemic cardiac toxicity in three out of four patients
and one patient experienced a QT prolongation. Non-specific
Table 3 Individual pharmacokinetic parameters of bendamustine in plasma
Subject
Dose (mgm
 2
per day) t1/2 (min) tmax (min) Cmax (ngml
 1)
AUCall
(minngml
 1)
AUCInf
(minngml
 1)V d (mlm
 2) Cl (mlminm
 2)
2 120 57.3 40 9011.5 490823.5 491145.7 24.3600 244.3
3 120 60.2 30 8907.3 540908.0 541672.9 19.2560 221.5
6 140 30.7 30 9978.4 437716.8 437991.4 14.1583 319.6
8 160 45.3 30 9966.1 448803.3 449333.0 23.2872 356.1
13 160 60.0 50 24474.6 1800220.3 1805225.4 7.6750 88.6
15 160 41.0 30 8797.7 444477.8 444631.4 21.2679 359.8
Mean 49.1 35.0 18.3341 265.0
s.d. 12.1 8.4 6.3460 103.6
Abbreviations: AUCInf¼AUC extrapolated to infinity; AUCall¼area under the plasma concentration time curve from time of dosing to last observation; Cl¼clearance; Cmax,
maximum peak concentration; s.d.¼standard deviation; t1/2¼half life; tmax, time to reach peak concentration; Vd¼volume of distribution.
Phase 1 study of chloride
M Rasschaert et al
1696
British Journal of Cancer (2007) 96(11), 1692–1698 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sT-wave changes and sinus tachycardia were seen at lower doses
with that regimen.
The present phase I study allowed for a higher dose intensity
(DI, 107mgm
 2 per week) at the recommended dose than found
with other schedules used in phase I studies (Table 4) or those
used in clinical practice so far. This observation is of importance
since a concentration-dependent efficacy has been described in
preclinical studies (Gandhi, 2002; Konstantinov et al, 2002;
Schwa ¨nen et al, 2002).
The estimated mean values of BM’s terminal half-live (t1/2)o f
49.1min and of its volume of distribution (Vd) of 18.3lm
 2 are not
different from those obtained in former pharmacokinetic evalua-
tions (Matthias et al, 1995).
In the present study, all mean values of tmax and t1/2 estimated
for the metabolites OH-BM, g-OH-BM and N-dimethyl-BM were in
the range of 35–64min and no dose dependency was evident for
these metabolites.
No valid evaluation could be performed for Di-OH-BM due to
too few data. Bendamustine and the hydrolysis products mono-
hydroxy and dihydroxy BM are open to chemical hydrolysis.
Therefore, the high variability of pharmacokinetic parameters
should be interpreted with caution.
This was particularly true for the urinary Pk data. As an
example, the highly variable amount of BM determined in urine
samples ranged from 0.8 to 50.2%, expressed as percentage of the
sum of all compounds quantified in this study. Therefore, for
evaluation, we decided to summarise amounts of BM and the two
hydrolysis products (OH-BM and Di-OH-BM) assuming undesir-
able hydrolysis during sampling period and/or sample preparation
before freezing. Hence, we calculated an amount excreted in urine
of 5.2 and 1.6% for g-OH-BM and N-dimethyl-BM, respectively,
expressed as the sum of all compounds quantified in this study.
These figures are in agreement with results observed in a previous
Pk study (Teichert et al, 2006).
In conclusion, BM hydrochloride given on a day 1þ2 q 3 weeks
schedule has predictable haematologic DLT and acceptable
nonhaematologic toxicities. Nevertheless, as in other phase I
experiences, fatigue remains an unpleasant side effect also with
this schedule. The recommended dose of 160mgm
 2 per day
seems to be safe and allows for a relatively high-dose intensity in
comparison with other schedules. However, considering the overall
low number of treatment cycles per patient in this phase I study,
additional information with this schedule in a more favourable
patient group seems warranted.
ACKNOWLEDGEMENTS
We thank Joke Dyck and Veerle Nys for data management,
Dr Mo ¨ller (Bioproof, Munich) and Professor Preiss (University of
Leipzig) for the analytical measurements and data supply and
ribosepharm GmbH, Munich, Germany for supporting this study.
REFERENCES
Barmam Balfour JA, Goa KL (2001) Bendamustine. Drugs 61: 631–640
Bergmann M, Goebeler M, Herold M, Emmerich B, Wilhelm M, Ruelfs C,
Boening L, Hallek M (2005) Efficacy of bendamustine in patients with
relapsed or refractory chronic lymphocytic leukemia: results of a phase I/
II study of the German CLL Study Group. Haematologica 90: 1357–1364
Bezek S, Kukan M, Scasna ´r V, Luka ´skova ´ M, Trnovec T (1996) Selective
uptake of the anticancer drug bendamustine by liver and kidney tissues
following its intravenous administration to mice. Methods Find Exp Clin
Pharmacol 18: 117–122
Bezek S, Scasna ´r V, Trnovec T, Grupe R (1991) Hepatobiliary elimination of
bendamustin (Cytosan
s) in rats. Pharmazie 46: 810–811
Bremer K (2002) High rates of long-lasting remissions after 5-day
bendamustine chemotherapy cycles in pre-treated low-grade non-
Hodgkin’s-lymphomas. J Cancer Res Clin Oncol 128: 603–609
Chow KU, Boehrer S, Geduldig K, Krapohl a, Hoelzer D, Mitrou P,
Weidmann E (2001) In vitro induction of apoptosis of neoplastic cells in
low-grade non-Hodgkin’s lymphomas using combinations of established
cytotoxic drugs with bendamustine. Haematologica 86: 485–493
Chow KU, Nowak D, Boerher S, Ruthardt M, Knau A, Hoelzer D, Mitrou P,
Weidmann E (2003) Synergistic effects of chemotherapeutic drugs in
lymphoma cells are associated with down-regulation of inhibitor of
apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4),
death-associated protein (Daxx) and with enforced caspase activation.
Biochem Pharmacol 66: 711–724
Friedberg J, Cohen P, Kerr R, Robinson KS, Forero-Torres A, van der Jagt
R, Camacho E, Hainsworth J, Roeck B, Multani P (2004) SDX-105
demonstrates a high response as a single-agent with acceptable safety in
rituximab-refractory, relapsed indolent or transformed non-Hodgkin’s
lymphoma (NHL). ASH Annual meeting abstracts 2004. Blood 104(11):
[abstract 2480]
Gandhi V (2002) Metabolism and mechanisms of action of bendamustine:
rationales for combination therapies. Sem Oncol 29(4 Suppl 13):
4–11
Heider A, Niederle N (2001) Efficacy and toxicity of bendamustine in
patients with relapsed low-grade non Hodgkin’s lymphomas. Anti-
Cancer Drugs 12: 725–729
Herold M, Schulze A, Niederwieser D, Franke A, Fricke HJ, Richter P,
Freund M, Ismer B, Dachselt K, Boewer C, Schirmer V, Weniger J, Pasold
R, Winkelmann C, Klinkenstein C, Schulze M, Arzberger H, Bremer K,
Hahnfeld S, Schwarzer A, Mu ¨ller C, Mu ¨ller Chr (2006) Bendamustine,
vincristine and prednisone (BOP) versus cyclophosphamide, vincristine
and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma
and mantle cell lymphoma: results of a randomised phase III trial
(OSHO# 19). J Cancer Res Clin Oncol 132: 105–112
Ho ¨ffken K, Merkle Kh, Scho ¨nfelder M, Anger G, Brandtner M, Ridwelski K,
Seeber S (1998) Bendamustine as salvage treatment in patients with
advanced progressive breast cancer: a phase II study. J Cancer Res Clin
Oncol 124: 627–632
Horn U, Ha ¨rtl A, Gu ¨ttner J, Hoffmann H (1985) Toxicity of the alkylating
agent Bendamustin. Arch Toxicol 8(Suppl): 504–506
Kanekal S, Crain B, Elliot G (2004) SDX-105 (Treandat) enhances the
tumor growth inhibitory effect of rituximab in daudi lymphoma
Table 4 Bendamustine in phase I (/II) studies
Author Phase n Bendamustine regimen MTD/RD (mgm
 2)D I ( m g m
 2week
 1)D L T
Scho ¨ffski et al I 19 d1, d8 q 4 weeks 160/140 80 Mouth dryness, fatigue
Scho ¨ffski et al I 12 Weekly 8 80/60 60 Mouth dryness, fatigue, fever
Rasschaert et al I 23 d1 q 3 weeks 280/260 87 Fatigue, cardiac toxicity
Bergmann et al CLL I/II 16 d1, d2 q 3–4 weeks 80/70 47–35 Granulocytopaenia, infection
Lissichkov et al CLL I/II 15 d1, d2 q 3–4 weeks 110/100 50 Bilirubinaemia
Diarrhoea
Present study I 15 d1, d2 q3 weeks 180/160 107 Thrombocytopaenia
Phase 1 study of chloride
M Rasschaert et al
1697
British Journal of Cancer (2007) 96(11), 1692–1698 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sxenografts, ASH annual meeting abstract 2004. Blood 104(11): [abstract
4580]
Konstantinov SM, Kostovski A, Topashka-Ancheva M, Genova M, Berger
MR (2002) Cytotoxic efficacy of bendamustine in human leukemia and
breast cancer cell lines. J Cancer Res Clin Oncol 128: 271–278
Leoni LM, Bailey B, Reifert J, Niemeyer C, Bendall H, Dauffenbach L,
Kerfoot C (2004) In vitro and ex vivo activity of SDX-105 (bendamustine)
in drug-resistant lymphoma cells. Proc Am Assoc Cancer Res 45, [abstract
1215]. (As indicated on the website of the AACR)
Lissitchkov T, Arnaudov G, Peytchev D, Merkle K (2006) Phase I/II study to
evaluate dose limiting toxicity, maximum tolerated dose, and tolerability
of bendamustine HCl in patients with B-chronic lymphocytic leukaemia
(Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 132:
99–104
Matthias M, Preiss R, Sohr R, Possinger K (1995) Pharmacokinetics of
bendamustin in patients with malignant tumors. Proc Am Soc Clin Oncol
14: 458 (abstract 1476)
Niemeyer C, Bailey B, Reifert J, Bendall H, Corbeil J, Leoni LM (2004) SDX-
105 (Bendamustine) is a clinically active chemotherapeutic agent with a
distinct mechanism of action. Proc Am Assoc Cancer Res 45, [abstract
1129]. (as indicated on the website of the AACR)
Ozegowski W, Krebs D (1963) w-[bid-(b-chloroethyl)-amino-benzimazolyl-
(2)]-propionic or butyric acids as potential cytotoxic agents. J Pract
Chem 20: 178–186
Po ¨nisch W, Mitrou PS, Merkle K, Herold M, Assmann M, Wilhelm G,
Dachselt K, Richter P, Schirmer V, Schulze A, ubert R, Harksel B, Grobe
N, Stelzer E, Schulze M, Bittrich A, Freund M, Pasold R, Friedrich T,
Helbig W, Niederwieser D (2006) Treatment of bendamustine and
prednisone in patients with newly diagnosed multiple myeloma results in
superior complete response rate, prolonged time to treatment failure and
improved quality of life compared to treatment with melphalan and
prednisone-a randomized phase III study of the East German Study
Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol
132(4): 205–212
Preiss R, Matthias M, Merkle KH (1998) Pharmacological and clinical data
of bendamustine. Proceedings of the 17th International Cancer Congress
Rio de Janeiro, 24–28 August 1998, Monduzzi Editore S.p.A. Bologna:
pp. 1637–1640
Pyke K, Tschakovsky M (2005) The relationship between shear sterss and
flow-mediated dilation: implications for the assessment of endothelial
function. J Physiol 568: 357–369
Rasschaert M, Schrijvers D, Van den Brande J, Dyck J, Bosmans J, Merkle
KH, Vermorken JB (2007) A phase I study of bendamustine hydro-
chloride administered once every three weeks in patients with solid
tumors. Anti Cancer Drugs 18: 587–595
Reck M, Haering B, Koschel G, Kaukel E, von Pawel J, Gatzemeier U (1998)
Chemotherapie des fortgeschrittenen nicht-kleinzelligen und kleinzelli-
gen bronchialkarzinoms mit bendamustin – Eine phase II Studie.
Pneumologie 52: 570–573
Rummel M, Al-Batran S, Kim S, Welslau M, Hecker R, Kofahl-Krause D,
Josten K, Du ¨rk H, Rost A, Neise M, von Gru ¨nhagen U, Chow K,
Hansmann M, Hoelzer D, Mitrou P (2005a) Bendamustine plus rituximab
is effective and has a favorable toxicity profile in the treatment of
mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol 23:
3383–3389
Rummel M, Al-Batran S, Welslau M, Kofahl-Krause D, Duerk H, Hoelzer D,
Mitrou P (2005b) Bendamustine and rituximab act synergistically in vitro
and are effective in the treatment of relapsed or refractory indolent and
mantle cell lymphomas. Proc Am Soc Clin Oncol 24: 576s (abstract 6565).
Schmittel A, Knodler M, Hortig P, Schulze K, Thiel E, Keilholz U (2007)
Phase II trial of second-line bendamustine chemotherapy in relapsed
small cell lung cancer patients. Lung Cancer 55(1): 109–113
Scho ¨ffski P, Hagedorn T, Gru ¨nwald V, Paul H, Merkle K, Kowalski R,
Ganser A (2000a) Repeated administration of short infusions of
bendamustine: a phase I study in patients with advanced progressive
solid tumours. J Cancer Res Clin Oncol 126: 41–47
Scho ¨ffski P, Seeland G, Engel H, Gru ¨nwald V, Paul H, Merkle K (2000b)
Weekly administration of bendamustine: a phase I study in patients with
advanced progressive solid tumours. Ann Oncol 11: 729–734
Schrijvers D, Vermorken JB (2002) Phase I studies with bendamustine: an
update. Semin Oncol 29(4 Suppl 13): 15–18
Schwa ¨nen C, Hecker T, Hu ¨binger G, Wo ¨lfe M, Rittgen W, Bergmann L,
Karakas T (2002) In vitro evaluation of bendamustine induced apoptosis
in B-chronic lymphocytic leukemia. Leukemia 16: 2096–2105
Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S. (1996)
Bendamustine hydrochloride activity against doxorubicin-resistant
human breast carcinoma cell lines. Anticancer Drugs 7: 415–421
Teichert J, Baumann F, Chao Q, Franklin C, Bailey B, Hennig L, Caca K,
Schoppmeyer K, Patzak U, Preiss R (2006) Characterization of two phase
I metabolites of bendamustine in human liver microsomes and in cancer
patients treated with bendamusitne hydrochloride. Cancer Chemother
Pharmacol September 7 [E-pub ahead of print].
Teichert J, Mockel J, Po ¨nisch W, Seidel A, Lotfi M, Matthias M (2003)
Influence of hepatic and renal function on the pharmacokinetics of
bendamustine. Int J Clin Pharmacol Ther 41: 564
Teichert J, Sohr R, Baumann F, Hennig L, Merkle K, caca K, Preiss R (2005)
Synthesis and characterization of some new phase II metabolites of the
alkylator bendamustine and their identification in human bile, urine and
plasma from patients with cholangiocarcinoma. Drug Metab Dispos 33:
984–992
Von Minckwitz G, Chernozemsky I, Sirakova L, Chilingirov P, Souchon R,
Marschner N, Kleeberg U, Tsekov C, Fritze D, Thomssen C, Stuart N,
Vermorken JB, Loibl S, Merkle Kh, Kaufmann M (2005) Bendamustine
prolongs progression-free survival in metastatic breast cancer (MBC): a
phase III prospective, randomized, multicenter trial of bendamustine
hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclopho-
sphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment
of MBC. Anticancer Drugs 16(8): 871–878
Weber H, Amlacher R, Preiss R, Hoffmann H (1991) Pharmakokinetik von
bendamustin (Cytostasan
s) in B6D2F1-Ma ¨usen. Pharmazie 46: 589–591
Weidmann E, Kim S, Rost A, Schuppert H, Seipelt G, Hoelzer D, Mitrou P
(2002) Bendamustine is effective in relapsed or refractory aggressive
non-Hodgkin’s lymphoma. Ann Oncol 13: 1285–1289
Zulkowski K, Kath R, Semrau R, Merkle Kh, Ho ¨ffken K (2002) Regression
of brain metastases from breast carcinoma after chemotherapy with
bendamustine. J Cancer Res Clin Oncol 128: 111–113
Phase 1 study of chloride
M Rasschaert et al
1698
British Journal of Cancer (2007) 96(11), 1692–1698 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s